Fig. 4.

Anti-PA Abs do not improve the protection conferred by Dalbavancin plus CpG-adjuvanted AVA. (A) A/J mice were challenged with 30 LD₅₀ of Sterne strain anthrax spores. 3 days later, they were treated with 150 μg of Dalbavancin plus CpG-adjuvanted AVA and/or 100 μl of high-titered anti-PA antiserum. This quantity of antiserum was protective if administered within 24 h of challenge. (B) A/J mice were immunized with CpG-adjuvanted AVA plus Dalbavancin alone or combined with 100 μl of high-titered anti-PA antiserum. These mice were challenged 1 month later with 30 LD₅₀ of Sterne strain anthrax spores. The percent improvement in survival vs. controls is shown (N = 8–10 mice/group). *p < .01 vs. animals treated with Dalbavancin.